Skip to main content

Table 1 Demographic and clinicopathologic characteristics of 308 subjects comprising ELISA study cohort and 173 subjects comprising IHC study cohort

From: Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection

  ELISA Cohort IHC Cohort
  BCa (%) n = 102 Controls (%) n = 206 BCa (%) n = 165 Controls (%) n = 8
Median Age (range, y) 69 (20 – 93) 56 (18 – 89) 67 (47 – 91) 59 (42 – 83)
Male : Female ratio 84 : 18 152 : 54 132 : 33 7 : 1
Race     
  White 91 (90%) 135 (66%) 137 (83%) 7 (88%)
  African American 5 (5.9%) 20 (10%) 8 (5%) 0 (0%)
  Other 6 (6.1%) 51 (24%) 20 (12%) 1 (12%)
Positive FISH 40 / 74 (54%) 2/22(9%) N/A N/A
Suspicious/positive cytology 37 / 94 (39%) 2/22(9%) N/A N/A
Median follow-up (months) 14 4 11 3
Clinical stage     
  Tis 6 (6%)   15 (9%)  
  Ta 41 (40%)   15 (9%)  
  T1 14 (14%)   15 (9%)  
  ≥T2 41 (40%)   120 (73%)  
Tumor grade     
  Low 38 (37%)   36 (22%)  
  High 64 (63%)   129 (78%)  
Median tumor size (cm) 3.0   3.5  
Median urinary CCL18 pg/ml (range) 52.84 11.13   
(2–6949) (0–662)
Median urinary A1AT ng/ml (range) 606.4 120.0   
(26–8830) (1–1997)
Median urinary protein μg/ml (range) 24.2 38.9   
  (24–789) (24–561)